Cutera (NASDAQ:CUTR) Downgraded by BidaskClub

BidaskClub cut shares of Cutera (NASDAQ:CUTR) from a buy rating to a hold rating in a research note issued to investors on Friday, BidAskClub reports.

Several other brokerages have also recently issued reports on CUTR. ValuEngine cut Cutera from a buy rating to a hold rating in a report on Tuesday, December 3rd. Stephens upped their target price on Cutera from $35.00 to $45.00 and gave the company an overweight rating in a report on Friday, November 8th. Finally, Zacks Investment Research upgraded Cutera from a hold rating to a buy rating and set a $42.00 target price for the company in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Cutera currently has an average rating of Hold and a consensus price target of $43.50.

Shares of NASDAQ:CUTR opened at $28.84 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.66 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $35.26 and a two-hundred day moving average of $31.62. The stock has a market cap of $414.76 million, a P/E ratio of -10.97 and a beta of 0.94. Cutera has a 52-week low of $13.10 and a 52-week high of $39.15.

Cutera (NASDAQ:CUTR) last issued its earnings results on Thursday, November 7th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.23. The company had revenue of $46.12 million during the quarter, compared to analysts’ expectations of $41.66 million. Cutera had a negative return on equity of 84.67% and a negative net margin of 20.84%. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.11 EPS. On average, equities analysts anticipate that Cutera will post -0.71 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. New York State Teachers Retirement System lifted its stake in shares of Cutera by 5.4% in the 4th quarter. New York State Teachers Retirement System now owns 21,413 shares of the medical device company’s stock valued at $767,000 after purchasing an additional 1,100 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Cutera in the 4th quarter valued at $79,000. Calamos Advisors LLC lifted its stake in shares of Cutera by 633.9% in the 4th quarter. Calamos Advisors LLC now owns 148,779 shares of the medical device company’s stock valued at $5,327,000 after purchasing an additional 128,507 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Cutera by 1.3% in the 3rd quarter. California State Teachers Retirement System now owns 21,548 shares of the medical device company’s stock valued at $630,000 after purchasing an additional 269 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Cutera by 25.8% in the 3rd quarter. State Street Corp now owns 465,757 shares of the medical device company’s stock valued at $13,614,000 after purchasing an additional 95,597 shares during the last quarter. 90.03% of the stock is currently owned by institutional investors and hedge funds.

About Cutera

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Featured Article: How to Trade Using Analysts Ratings

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.